GCVI Summit 2018
Skip Content

20 April 2017

CanSino raises $65m from high rollers

Existing investor Lilly Asia Ventures returned to take part in a round that will support the late stage development and commercialisation of four vaccine candidates.

Author: Robert Lavine, News Editor

China-based vaccine developer Tianjin CanSino Biotechnology closed a $65m funding round on Tuesday backed by Lilly Asia Ventures, a strategic investment vehicle for pharmaceutical company Eli Lilly.